This activity is composed of 3 interactive case studies that explore the use of incretin-based therapies for addressing type 2 diabetes (T2D) disease pathophysiology as well as individualized treatment approaches. Glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors are incretin-based therapies introduced in the last 5 years. GLP-1 receptor agonists and DPP-4 inhibitors address multiple pathophysiological defects of T2D and may be appropriate treatment options for many patients. Given the increasing abundance of data for these agents and recent treatment algorithm updates regarding their use, physicians, nurses (RNs), certified diabetes educators (CDEs) and other healthcare providers (HCPs) who treat patients with diabetes are likely to benefit from examining strategies for implementing incretin-based therapies through several diverse clinical scenarios. This free educational patient case study provides this opportunity.